AN2 Therapeutics, Inc.
ANTX- 1M
- -8.9%
AN2 Therapeutics, Inc. in brief
AN2 Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Menlo Park, California, USA. It was founded in 2017. Its market value was $172 M on 29 October 2026, which makes it the 16,823rd largest listed company in the world and the 3,246th largest in the USA on this site. Eric Easom is its chief executive. Its shares trade under the symbol ANTX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc is a biopharmaceutical company develops therapeutics to treat rare, chronic and serious infectious diseases in areas of high unmet medical need. The headquarters is in United States.
AN2 Therapeutics, Inc. timeline
- 2017
- 🏁· approximateFounded
- 2021
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2022
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 28 March 2022; shares registered for exchange trading on 22 March 2022.
Events of AN2 Therapeutics, Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,760 (Dec 2022) · #3,800 (Jul 2023) · #2,419 (Jan 2024) · #2,012 (Mar 2026) · #3,038 (Aug 2026) · #3,172 (Sep 2026) · #3,250 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 3.2×
- Free cash flow yield
- —
- Net margin
- —
- Operating margin
- —
- Return on equity
- -66.3%
- Liabilities / assets
- 14.4%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-38M | $-35M | — |
| Dec 2024 | — | — | $-57M | $-51M | — |
| Dec 2023 | — | — | $-70M | $-65M | — |
| Dec 2022 | — | — | $-42M | $-41M | — |
| Dec 2021 | — | — | $-22M | $-22M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-30M | — | — | $-1.16 | — |
| Dec 2024 | $-49M | — | — | $-1.72 | — |
| Dec 2023 | $-53M | — | — | $-2.74 | — |
| Dec 2022 | $-33M | — | — | $-2.79 | — |
| Dec 2021 | $-20M | — | — | $-10.64 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-8M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Nov 9, 20268-KCurrent reportResults of operations
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Aug 11, 20268-KCurrent reportResults of operations
- Jun 9, 20268-KCurrent reportShareholder vote
- Jun 4, 20268-KCurrent reportRegulation FD disclosure · Other events
- May 11, 202610-QQuarterly report · period to Mar 2026
- May 11, 20268-KCurrent reportResults of operations
- Apr 22, 2026DEF 14AProxy statement
- Apr 9, 20268-KCurrent reportOther events
- Mar 20, 20268-KCurrent reportDirectors or officers changed
- Mar 17, 202610-KAnnual report · period to Dec 2025
Official filings of AN2 Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-38 M
- Net income
- $-35 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $62 M
- Total liabilities
- $9 M
- Total equity
- $53 M
As of December-2025
Top 88 institutional investors in AN2 Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vivo Capital, LLC | 3,153,640 | 0 (0.00%) | 8.31% | $17 M | Nov 13, 2026 |
| 2 | Commodore Capital LP | 2,933,680 | 0 (0.00%) | 7.73% | $16 M | Nov 16, 2026 |
| 3 | Millennium Management LLC | 2,476,231 | +157,539 (+6.79%) | 6.53% | $13 M | Nov 16, 2026 |
| 4 | BlackRock, Inc. | 1,771,563 | +106,069 (+6.37%) | 4.67% | $9 M | Nov 13, 2026 |
| 5 | Spruce Street Capital LP | 1,752,011 | +90,938 (+5.47%) | 4.62% | $9 M | Nov 13, 2026 |
| 6 | Acorn Capital Advisors, LLC | 1,300,000 | New | 3.43% | $7 M | Nov 16, 2026 |
| 7 | Vanguard Capital Management LLC | 1,238,705 | 0 (0.00%) | 3.26% | $7 M | Nov 13, 2026 |
| 8 | Adage Capital Partners GP, L.L.C. | 1,000,000 | 0 (0.00%) | 2.64% | $5 M | Nov 16, 2026 |
| 9 | Citadel Advisors LLC | 984,080 | +32,083 (+3.37%) | 2.59% | $5 M | Nov 16, 2026 |
| 10 | Boxer Capital Management, LLC | 944,035 | +195,000 (+26.03%) | 2.49% | $5 M | Nov 16, 2026 |
| 11 | Geode Capital Management, LLC | 684,122 | -13,684 (-1.96%) | 1.80% | $4 M | Nov 6, 2026 |
| 12 | Goldman Sachs Group Inc | 634,655 | +546,722 (+621.75%) | 1.67% | $3 M | Nov 16, 2026 |
| 13 | Tetragon Partners GP Ltd | 603,424 | New | 1.59% | $3 M | Nov 16, 2026 |
| 14 | SummitTX Capital, L.P. | 597,793 | +340 (+0.06%) | 1.58% | $3 M | Nov 16, 2026 |
| 15 | Sio Capital Management, LLC | 548,103 | +18,170 (+3.43%) | 1.44% | $3 M | Nov 16, 2026 |
| 16 | Ameriprise Financial Inc | 537,225 | +161 (+0.03%) | 1.42% | $3 M | Nov 16, 2026 |
| 17 | Ally Bridge Group (NY) LLC | 526,315 | 0 (0.00%) | 1.39% | $3 M | Nov 16, 2026 |
| 18 | Woodline Partners LP | 447,420 | -12,385 (-2.69%) | 1.18% | $2 M | Nov 16, 2026 |
| 19 | State Street Corp | 444,468 | +132,866 (+42.64%) | 1.17% | $2 M | Nov 12, 2026 |
| 20 | Stonepine Capital Management, LLC | 350,877 | -200,815 (-36.40%) | 0.92% | $2 M | Nov 13, 2026 |
| 21 | Prosight Management, LP | 350,877 | -123,761 (-26.07%) | 0.92% | $2 M | Nov 13, 2026 |
| 22 | Almitas Capital LLC | 349,068 | -1,120,061 (-76.24%) | 0.92% | $2 M | Nov 17, 2026 |
| 23 | Balyasny Asset Management L.P. | 287,250 | -268,777 (-48.34%) | 0.76% | $2 M | Nov 16, 2026 |
| 24 | BNP Paribas Financial Markets | 255,878 | +245,693 (+2412.30%) | 0.67% | $1 M | Nov 12, 2026 |
| 25 | Seven Fleet Capital Management LP | 254,309 | +45,363 (+21.71%) | 0.67% | $1 M | Nov 16, 2026 |
Show all 88: investors 26 to 88
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | UBS Group AG | 251,686 | +177,600 (+239.72%) | 0.66% | $1 M | Nov 10, 2026 |
| 27 | Russell Investments Group, Ltd. | 222,225 | +220,113 (+10422.02%) | 0.59% | $1 M | Nov 6, 2026 |
| 28 | Northern Trust Corp | 209,978 | -4,943 (-2.30%) | 0.55% | $1 M | Nov 16, 2026 |
| 29 | Vanguard Fiduciary Trust Co | 195,856 | -1,064 (-0.54%) | 0.52% | $1 M | Nov 13, 2026 |
| 30 | Vanguard Portfolio Management LLC | 180,924 | +1,330 (+0.74%) | 0.48% | $1 M | Nov 13, 2026 |
| 31 | Acuta Capital Partners, LLC | 142,051 | New | 0.37% | $1 M | Nov 16, 2026 |
| 32 | Marshall Wace, LLP | 106,143 | New | 0.28% | $1 M | Nov 13, 2026 |
| 33 | Morgan Stanley | 81,631 | +32,252 (+65.32%) | 0.22% | $0 M | Nov 13, 2026 |
| 34 | Renaissance Technologies LLC | 80,100 | -49,600 (-38.24%) | 0.21% | $0 M | Nov 12, 2026 |
| 35 | Toronto Dominion Bank | 78,025 | New | 0.21% | $0 M | Nov 16, 2026 |
| 36 | Dimensional Fund Advisors LP | 76,045 | 0 (0.00%) | 0.20% | $0 M | Nov 4, 2026 |
| 37 | Bank of New York Mellon Corp | 67,865 | +189 (+0.28%) | 0.18% | $0 M | Nov 5, 2026 |
| 38 | Charles Schwab Investment Management Inc | 64,220 | 0 (0.00%) | 0.17% | $0 M | Nov 16, 2026 |
| 39 | Bridgeway Capital Management, LLC | 60,909 | +1,009 (+1.68%) | 0.16% | $0 M | Nov 16, 2026 |
| 40 | ADAR1 Capital Management, LLC | 58,808 | 0 (0.00%) | 0.15% | $0 M | Nov 16, 2026 |
| 41 | Empowered Funds, LLC | 58,009 | New | 0.15% | $0 M | Nov 13, 2026 |
| 42 | Captrust Financial Advisors | 41,297 | +1,132 (+2.82%) | 0.11% | $0 M | Nov 12, 2026 |
| 43 | Bank Of America Corp /de/ | 40,317 | -105,486 (-72.35%) | 0.11% | $0 M | Nov 16, 2026 |
| 44 | Velan Capital Investment Management LP | 40,000 | 0 (0.00%) | 0.11% | $0 M | Nov 16, 2026 |
| 45 | Walleye Capital LLC | 39,972 | -32,167 (-44.59%) | 0.11% | $0 M | Nov 13, 2026 |
| 46 | Nuveen, LLC | 35,423 | +90 (+0.25%) | 0.09% | $0 M | Nov 10, 2026 |
| 47 | Rhumbline Advisers | 32,975 | +8,633 (+35.47%) | 0.09% | $0 M | Nov 10, 2026 |
| 48 | American Century Companies Inc | 25,696 | New | 0.07% | $0 M | Nov 12, 2026 |
| 49 | Deutsche Bank AG\ | 22,495 | -3,343 (-12.94%) | 0.06% | $0 M | Nov 6, 2026 |
| 50 | Price T Rowe Associates Inc /MD/ | 22,022 | 0 (0.00%) | 0.06% | $0 M | Nov 16, 2026 |
| 51 | Quadrature Capital Ltd | 20,735 | New | 0.05% | $0 M | Nov 13, 2026 |
| 52 | Gsa Capital Partners LLP | 20,603 | New | 0.05% | $0 M | Nov 16, 2026 |
| 53 | FMR LLC | 17,753 | +17,692 (+29003.28%) | 0.05% | $0 M | Nov 10, 2026 |
| 54 | WINTON GROUP Ltd | 16,150 | New | 0.04% | $0 M | Nov 12, 2026 |
| 55 | Invesco Ltd. | 13,890 | +51 (+0.37%) | 0.04% | $0 M | Nov 12, 2026 |
| 56 | Connor, Clark & Lunn Investment Management Ltd. | 13,603 | New | 0.04% | $0 M | Nov 10, 2026 |
| 57 | Vanguard Global Advisers, LLC | 13,449 | +6,115 (+83.38%) | 0.04% | $0 M | Nov 13, 2026 |
| 58 | Jpmorgan Chase & Co | 12,981 | +2,010 (+18.32%) | 0.03% | $0 M | Nov 12, 2026 |
| 59 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 12,856 | +670 (+5.50%) | 0.03% | $0 M | Nov 16, 2026 |
| 60 | LPL Financial LLC | 12,350 | 0 (0.00%) | 0.03% | $0 M | Nov 6, 2026 |
| 61 | Algert Global LLC | 11,920 | New | 0.03% | $0 M | Nov 17, 2026 |
| 62 | Bronte Capital Management Pty Ltd. | 10,895 | 0 (0.00%) | 0.03% | $0 M | Nov 12, 2026 |
| 63 | Barclays PLC | 10,305 | +4,814 (+87.67%) | 0.03% | $0 M | Nov 6, 2026 |
| 64 | Acadian Asset Management LLC | 10,160 | New | 0.03% | $0 M | Nov 9, 2026 |
| 65 | Engineers Gate Manager LP | 10,143 | New | 0.03% | $0 M | Nov 16, 2026 |
| 66 | Mangrove Partners Im, LLC | 10,139 | New | 0.03% | $0 M | Nov 16, 2026 |
| 67 | Police & Firemen's Retirement System of New Jersey | 8,615 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 68 | Royal Bank Of Canada | 5,544 | +4,606 (+491.04%) | 0.01% | $0 M | Nov 16, 2026 |
| 69 | Wells Fargo & Company/mn | 5,476 | -16,913 (-75.54%) | 0.01% | $0 M | Nov 16, 2026 |
| 70 | New York State Common Retirement Fund | 5,000 | 0 (0.00%) | 0.01% | $0 M | Nov 17, 2026 |
| 71 | Tower Research Capital LLC (TRC) | 3,305 | +1,498 (+82.90%) | 0.01% | $0 M | Nov 16, 2026 |
| 72 | Legal & General Group Plc | 2,576 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 73 | Ameritas Investment Partners, Inc. | 2,402 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 74 | PNC Financial Services Group, Inc. | 1,438 | New | 0.00% | $0 M | Nov 6, 2026 |
| 75 | Citigroup Inc | 1,291 | -10,976 (-89.48%) | 0.00% | $0 M | Nov 4, 2026 |
| 76 | State of Wyoming | 603 | New | 0.00% | $0 M | Oct 28, 2026 |
| 77 | Sterling Capital Management LLC | 562 | +78 (+16.12%) | 0.00% | $0 M | Oct 22, 2026 |
| 78 | Federated Hermes, Inc. | 341 | -108 (-24.05%) | 0.00% | $0 M | Nov 12, 2026 |
| 79 | Osaic Holdings, Inc. | 300 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 80 | SBI Securities Co., Ltd. | 201 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 81 | GAMMA Investing LLC | 191 | New | 0.00% | $0 M | Oct 8, 2026 |
| 82 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 177 | New | 0.00% | $0 M | Nov 16, 2026 |
| 83 | Fortitude Family Office, LLC | 90 | New | 0.00% | $0 M | Oct 14, 2026 |
| 84 | Allworth Financial LP | 38 | New | 0.00% | $0 M | Nov 17, 2026 |
| 85 | SJS Investment Consulting Inc. | 36 | New | 0.00% | $0 M | Oct 26, 2026 |
| 86 | Root Financial Partners, LLC | 24 | New | 0.00% | $0 M | Oct 21, 2026 |
| 87 | Caitong International Asset Management Co., Ltd | 13 | -261 (-95.26%) | 0.00% | $0 M | Oct 29, 2026 |
| 88 | Arax Advisory Partners | 2 | New | 0.00% | $0 M | Nov 12, 2026 |
Mutual funds holding AN2 Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 853,017 | $4 M | 2.2% | <0.01% | +16% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 603,086 | $3 M | 1.6% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 360,114 | $2 M | 0.95% | <0.01% | +43% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 289,229 | $2 M | 0.76% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 195,477 | $1 M | 0.52% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 122,776 | $1 M | 0.32% | <0.01% | +7.0% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 88,850 | $0 M | 0.23% | 0.03% | +67% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 64,220 | $0 M | 0.17% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 59,000 | $0 M | 0.16% | 0.19% | no change | Jun 30, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 49,470 | $0 M | 0.13% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 48,504 | $0 M | 0.13% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 35,333 | $0 M | 0.09% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 35,294 | $0 M | 0.09% | <0.01% | +34% | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 32,907 | $0 M | 0.09% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 29,717 | $0 M | 0.08% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 34,964 | $0 M | 0.09% | <0.01% | +16% | May 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 29,625 | $0 M | 0.08% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 27,514 | $0 M | 0.07% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 20,300 | $0 M | 0.05% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 19,633 | $0 M | 0.05% | <0.01% | +40% | May 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 15,448 | $0 M | 0.04% | <0.01% | +82% | Jul 31, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 12,656 | $0 M | 0.03% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 13,726 | $0 M | 0.04% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 12,781 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 12,793 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 10,600 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 8,043 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 7,333 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 6,193 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 5,962 | $0 M | 0.02% | 0.01% | +52% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 5,831 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 5,803 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 4,147 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 4,037 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 3,416 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 3,536 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 3,466 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 3,099 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 3,042 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 2,862 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 2,600 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 2,600 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 2,314 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 2,402 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 2,112 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 1,911 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 1,096 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 986 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 669 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 668 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 574 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 230 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 200 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 53 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at AN2 Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Joshua M. EizenSee Remarks | Sell | -2,826 | $4.220 | $12 K | 207,546 | Form 4 |
| filed | Kabeer AzizDirector | Grant or award | +2,465 | — | — | 61,571 | Form 4 |
| filed | Patricia A. MartinDirector | Grant or award | +389 | — | — | 19,252 | Form 4 |
| filed | Gilbert Lynn MarksDirector | Grant or award | +2,283 | — | — | 84,156 | Form 4 |
| filed | Cameron C. Trenor IIIChief Medical Officer | Grant or award | +116,667 | — | — | 116,667 | Form 4 |
| filed | Robin Shane ReadnourDirector | Sell10b5-1 plan · indirect | -523 | $6.020 | $3 K | 557,467 | Form 4 |
| filed | Robin Shane ReadnourDirector | Sell10b5-1 plan · indirect | -585 | $6.020 | $4 K | 624,765 | Form 4 |
| filed | Robin Shane ReadnourDirector | Sell10b5-1 plan · indirect | -4,725 | $6.020 | $28 K | 557,990 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: AN2 Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 2.353-for-1 split
Fails to deliver
- : 55,333 shares at $4.52
- : 466 shares at $3.63
- : 472 shares at $3.55
- : 2,325 shares at $3.37
- : 3,427 shares at $4.96
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
AN2 Therapeutics, Inc. scorecard#
Passes 2 of the 10 checks that could be worked out. Fiscal year 2025; market cap of Oct 29, 2026.
Valuation0 of 3
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median3.2×Price to book 3.2× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.16 vs -1.72Diluted EPS -1.16 in fiscal 2025 against -1.72 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$35 MNet income -$35 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-52.1%-52.1% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities6.9×Current ratio 6.87 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year1.3%Diluted shares up 1.3% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
AN2 Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Research and development | 25−38.8%— | 40−26.2%— | 55+92.5%— | 29+76.5%— | 16—— | |
| General and administrative | 13−5.2%— | 14−4.7%— | 15+15.8%— | 13+173%— | 4.7—— | |
| Operating expenses | 38−32.9%— | 57−18.4%— | 70+64.8%— | 42+95.9%— | 22—— | |
| Operating income | −38—— | −57—— | −70—— | −42—— | −22—— | |
| Interest and finance income | 2.9−46.3%— | 5.5r5.5+12.5%— | 4.9—— | — | — | |
| Other non-operating income (expense) | 0.00.0%— | 0.0−97.7%— | 0.0r4.9−96.7%— | 1.3r−0.0—— | −0.0—— | |
| Income tax | 0—— | 0—— | 0—— | 0—— | 0—— | |
| Net income including minority interests | −35—— | −51—— | −65—— | −41—— | −22—— | |
| Net income attributable to shareholders | −35—— | −51—— | −65—— | −41—— | −22—— | |
| Earnings per share, basic | -1.16—— | -1.72—— | -2.74—— | -2.79—— | -10.64—— | |
| Earnings per share, diluted | -1.16—— | -1.72—— | -2.74—— | -2.79—— | -10.64—— | |
| Shares, weighted average (basic) | 30+1.3%— | 30+26.4%— | 24+53.8%— | 15+481%— | 2.6—— | |
| Shares, weighted average (diluted) | 30+1.3%— | 30+26.4%— | 24+53.8%— | 15+481%— | 2.6—— | |
| Balance sheet | ||||||
| Cash and cash equivalents | 20−6.6%32.2% | 21+36.5%23.2% | 16−42.5%11.3% | 27+125%26.5% | 12—18.5% | |
| Short-term investments | 38−38.9%61.4% | 62−32.1%67.6% | 92+33.1%66.1% | 69+48.2%67.1% | 46—71.1% | |
| Other current assets | 1.9−26.8%3.1% | 2.6−17.7%2.9% | 3.2+28.0%2.3% | 2.5+61.8%2.4% | 1.6—2.4% | |
| Current assets | 60−30.5%96.8% | 86−21.9%93.7% | 111+12.1%79.6% | 99+64.1%96.2% | 60—92.0% | |
| Total assets | 62−32.7%100% | 92−33.6%100% | 139+35.3%100% | 103+57.0%100% | 65—100% | |
| Accounts payable | 3.0−8.9%4.9% | 3.3+24.0%3.6% | 2.7+26.1%1.9% | 2.1+99.6%2.1% | 1.1—1.6% | |
| Current liabilities | 8.7−14.8%14.1% | 10−27.1%11.1% | 14+95.4%10.1% | 7.2+112%7.0% | 3.4—5.2% | |
| Total liabilities | 8.9−13.2%14.4% | 10−27.1%11.1% | 14+95.4%10.1% | 7.2+111%7.0% | 3.4—5.2% | |
| Retained earnings | −241—−389% | −206—−223% | −154—−111% | −90—−87.5% | −47—−72.5% | |
| Shareholders' equity | 53−35.2%85.6% | 82−34.4%88.9% | 125+30.8%89.9% | 95—93.0% | −47—−72.6% | |
| Total liabilities and equity | 62−32.7%100% | 92−33.6%100% | 139+35.3%100% | 103+57.0%100% | 65—100% | |
| Shares outstanding | 27−8.4%— | 30+0.6%— | 30+53.3%— | 19+611%— | 2.7—— | |
| Cash-flow statement | ||||||
| Share-based compensation | 6.2−25.1%— | 8.3−0.9%— | 8.4+91.6%— | 4.4+351%— | 1.0—— | |
| Cash from operating activities | −30—— | −49—— | −53—— | −33—— | −20—— | |
| Cash from investing activities | 28−48.1%— | 55—— | −43—— | −22—— | −50—— | |
| Shares issued | 0.1−41.5%— | 0.1−59.8%— | 0.4—— | — | — | |
| Cash from financing activities | 0.1−69.6%— | 0.4−99.6%— | 85+20.8%— | 70−10.4%— | 79—— | |
| Change in cash | −1.4−125%— | 5.7—— | −12−177%— | 15+88.4%— | 8.0—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 25+8.9%— | 5.7−18.2%— | 6.0+88.1%— | 6.7−12.3%— | 6.9*+27.5%— | 7.0−15.5%— | 3.2−73.7%— | 7.7−47.5%— | 5.4*−63.8%— | 8.3—— | 12—— | 15—— | 15*—— | |
| General and administrative | 12−14.4%— | 2.9−3.1%— | 2.9−28.2%— | 3.8−1.0%— | 2.4*−24.1%— | 3.0−12.7%— | 4.0+7.6%— | 3.8+5.7%— | 3.2*−17.6%— | 3.5—— | 3.7—— | 3.6—— | 3.9*—— | |
| Operating expenses | 37+0.1%— | 8.7−13.6%— | 8.9+23.4%— | 11−8.5%— | 9.3*+8.4%— | 10−28.4%— | 7.2−54.6%— | 12−36.9%— | 8.6*−54.3%— | 14—— | 16—— | 18—— | 19*—— | |
| Operating income | −37—— | −8.7—— | −8.9—— | −11—— | −9.3*—— | −10—— | −7.2—— | −12—— | −8.6*—— | −14—— | −16—— | −18—— | −19*—— | |
| Interest and finance income | 2.6−24.8%— | 0.7+3.8%— | 0.7−4.5%— | 0.5−41.1%— | 0.6*−43.8%— | 0.7−45.8%— | 0.8−47.8%— | 0.9−47.1%— | 1.1r1.1*—— | 1.3—— | 1.4—— | 1.7—— | — | |
| Other non-operating income (expense) | — | 0*—— | −0.0—— | — | — | — | — | — | 0*—— | 1.3—— | 0r1.4—— | 0.0r1.7—— | −2.9r1.9*—— | |
| Net income including minority interests | −35—— | −8.0*—— | −8.2*—— | −10—— | −8.7*—— | −9.4*—— | −6.5*—— | −11—— | −7.5*—— | −13*—— | −14*—— | −17—— | −17*—— | |
| Net income attributable to shareholders | −35—— | −8.0—— | −8.2—— | −10—— | −8.7*—— | −9.4—— | −6.5—— | −11—— | −7.5*—— | −13—— | −14—— | −17—— | −17r−17*—— | |
| Earnings per share, basic | — | -0.17—— | -0.18—— | -0.29—— | — | -0.31—— | -0.21—— | -0.35—— | — | -0.43—— | -0.48—— | -0.56—— | — | |
| Earnings per share, diluted | — | -0.17—— | -0.18—— | -0.29—— | — | -0.31—— | -0.21—— | -0.35—— | — | -0.43—— | -0.48—— | -0.56—— | — | |
| Shares, weighted average (basic) | 46+52.3%— | 46+52.3%— | 45+48.4%— | 34+13.3%— | — | 30+1.5%— | 30+1.2%— | 30+1.0%— | — | 30—— | 30—— | 30—— | — | |
| Shares, weighted average (diluted) | 46+52.3%— | 46+52.3%— | 45+48.4%— | 34+13.3%— | — | 30+1.5%— | 30+1.2%— | 30+1.0%— | — | 30—— | 30—— | 30—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 20—24.7% | 20+12.2%24.7% | 44+143%54.3% | 53+168%61.1% | 20−6.6%32.2% | 18−46.3%26.8% | 18−31.9%24.0% | 20−19.1%24.6% | 21+36.5%23.2% | 34—34.3% | 27—24.7% | 25—20.4% | 16—11.3% | |
| Short-term investments | 44—53.9% | 44+0.6%53.9% | 34−23.8%41.7% | 32−32.4%36.3% | 38−38.9%61.4% | 44−26.7%65.3% | 45−42.5%58.9% | 47−47.4%57.9% | 62−32.1%67.6% | 60—61.3% | 78—71.7% | 90—73.8% | 92—66.1% | |
| Other current assets | 1.4—1.7% | 1.4−34.9%1.7% | 1.6−65.2%2.0% | 2.2−11.8%2.5% | 1.9−26.8%3.1% | 2.1−50.9%3.1% | 4.6+59.0%6.1% | 2.5+18.8%3.1% | 2.6−17.7%2.9% | 4.3—4.4% | 2.9—2.7% | 2.1—1.7% | 3.2—2.3% | |
| Current assets | 66—80.2% | 66+2.7%80.2% | 80+18.5%97.9% | 87+25.8%100% | 60−30.5%96.8% | 64−34.5%95.2% | 68−37.2%89.1% | 70−40.2%85.5% | 86−21.9%93.7% | 98—100% | 107—99.0% | 116—95.9% | 111—79.6% | |
| Total assets | 82—100% | 82+21.9%100% | 82+7.7%100% | 87+7.6%100% | 62−32.7%100% | 67−31.2%100% | 76−30.1%100% | 81−32.9%100% | 92−33.6%100% | 98—100% | 108—100% | 121—100% | 139—100% | |
| Accounts payable | 1.7—2.0% | 1.7−25.3%2.0% | 2.0−6.9%2.4% | 2.6−14.9%3.0% | 3.0−8.9%4.9% | 2.2+30.1%3.3% | 2.1+12.1%2.8% | 3.1+26.3%3.8% | 3.3+24.0%3.6% | 1.7—1.8% | 1.9—1.7% | 2.4—2.0% | 2.7—1.9% | |
| Current liabilities | 6.3—7.7% | 6.3—7.7% | 5.6—6.8% | 5.6—6.4% | 8.7−14.8%14.1% | — | — | — | 10−27.1%11.1% | 10—10.3% | — | — | 14—10.1% | |
| Total liabilities | 6.4—7.9% | 6.4−6.0%7.9% | 5.8−17.6%7.0% | 5.7−28.5%6.6% | 8.9−13.2%14.4% | 6.9−31.5%10.2% | 7.0−31.0%9.2% | 8.0−24.8%9.9% | 10−27.1%11.1% | 10—10.3% | 10—9.3% | 11—8.8% | 14—10.1% | |
| Retained earnings | −267—−326% | −267—−326% | −259—−317% | −251—−287% | −241—−389% | −232—−345% | −223—−294% | −216—−266% | −206—−223% | −198—−203% | −186—−171% | −171—−141% | −154—−111% | |
| Shareholders' equity | 76—92.1% | 76+25.1%92.1% | 76+10.3%93.0% | 82+11.5%93.4% | 53−35.2%85.6% | 60−31.1%89.8% | 69−30.0%90.8% | 73−33.7%90.1% | 82−34.4%88.9% | 88—89.7% | 98—90.7% | 111—91.2% | 125—89.9% | |
| Total liabilities and equity | 82—100% | 82+21.9%100% | 82+7.7%100% | 87+7.6%100% | 62−32.7%100% | 67−31.2%100% | 76−30.1%100% | 81−32.9%100% | 92−33.6%100% | 98—100% | 108—100% | 121—100% | 139—100% | |
| Shares outstanding | 38—— | 38+38.4%— | 36+32.6%— | 36+19.4%— | 27−8.4%— | 27−8.4%— | 27−8.2%— | 30+1.1%— | 30+0.6%— | 30—— | 30—— | 30—— | 30—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 4.8−27.5%— | 1.0+21.5%— | 1.0−51.4%— | 1.5−28.7%— | 1.4*−21.3%— | 0.8−57.9%— | 2.0−12.0%— | 2.0−14.2%— | 1.8*−20.3%— | 1.9—— | 2.3—— | 2.4—— | 2.2*—— | |
| Cash from operating activities | −30—— | −6.1*—— | −7.0*—— | −12—— | −5.2*—— | −6.4*—— | −7.6*—— | −11—— | −5.3*—— | −12*—— | −14*—— | −18—— | −17*—— | |
| Cash from investing activities | −13−189%— | −24*−500%— | −3.7*−163%— | 8.3−9.8%— | 7.2*—— | 6.1*−67.4%— | 5.8*−64.6%— | 9.2−65.0%— | −6.9*−1738%— | 19*—— | 16*—— | 26—— | 0.4*—— | |
| Shares issued | — | — | — | — | 0*—— | 0.0*+109%— | 0*—— | 0.0−69.4%— | 0*—— | 0.0*—— | 0*—— | 0.1—— | 0*—— | |
| Cash from financing activities | 45+39944%— | 6.4*+13300%— | 1.5*—— | 37+57329%— | 0*—— | 0.0*+109%— | 0*—— | 0.1−81.4%— | 0*—— | 0.0*—— | 0*—— | 0.3—— | −0.3*—— | |
| Change in cash | 2.2—— | −24*—— | −9.2*—— | 34—— | 1.9*—— | −0.2*−103%— | −1.8*−185%— | −1.4−115%— | −12*—— | 6.7*—— | 2.1*—— | 9.0—— | −17*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at AN2 Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Restructuring 1 · Directors and officers 4 · Material agreement 2 · Unregistered share sale 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Unregistered share sale | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Material agreementShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| RestructuringDirectors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2026 | $40 M | Private placement after listing | $10 to $50 million | 16 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How AN2 Therapeutics, Inc. compares in Biotechnology
- Market cap$172 M · higher than 42% of 726
- Price / book3.2× · lower than 46% of 534
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| AN2 Therapeutics, Inc.🇺🇸 | $172 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at AN2 Therapeutics, Inc.? Verify and update this profile — free
Show AN2 Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.